T1	p 125 204	in patients with hemodynamically decompensated heart failure . BACKGROUND Human
T2	p 282 313	decompensated cardiac failure .
T3	p 427 446	human heart failure
T4	p 540 607	16 decompensated heart failure patients in an invasive , randomized
T5	p 939 947	patients
T6	p 951 965	the hBNP group
T7	p 1958 1987	decompensated heart failure .
T8	i 105 116	natriuretic
T9	i 233 237	hBNP
T10	i 516 520	hBNP
T11	i 625 643	placebo-controlled
T12	i 733 744	( placebo [
T13	i 760 764	hBNP
T14	i 779 797	microgram/kg/min [
T15	i 815 829	post-treatment
T16	i 1425 1432	placebo
T17	o 15 26	hemodynamic
T18	o 29 42	neurohormonal
T19	o 49 62	renal effects
T20	o 371 376	renal
T21	o 832 853	Urinary volume losses
T22	o 1009 1030	adverse events . hBNP
T23	o 1066 1126	right atrial pressure and pulmonary capillary wedge pressure
T24	o 1207 1235	systemic vascular resistance
T25	o 1356 1369	cardiac index
T26	o 1400 1412	heart rate .
T27	o 1450 1508	plasma norepinephrine and aldosterone . Renal hemodynamics
T28	o 1701 1729	systemic vascular resistance
T29	o 1755 1850	cardiac output without increasing heart rate . 3 ) Plasma norepinephrine and aldosterone levels